NC
SWTX

NinePointTwo Capital’s SpringWorks Therapeutics SWTX Stock Holding History

NinePointTwo Capital’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,824
Closed -$281K – 308
2022
Q4 		$281K Buy
+10,824
New +$267K 0.12% 41

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

NinePointTwo Capital's SWTX Position: Q1 2023 in Review

NinePointTwo Capital sold out of SpringWorks Therapeutics (SWTX) in Q1 2023, closing a stake of 10,824 shares — an estimated $281K sold.

NinePointTwo Capital first reported a position in SWTX in Q4 2022 and held it in 1 quarter. The position peaked at $281K in Q4 2022. 148 funds tracked by Wall St. Rank hold SWTX as of Q1 2023.

  • NinePointTwo Capital reported no remaining SpringWorks Therapeutics position as of Q1 2023 after selling out during the quarter.
  • NinePointTwo Capital sold 10,824 SpringWorks Therapeutics shares in Q1 2023, an estimated $281K.
  • NinePointTwo Capital first reported a position in SpringWorks Therapeutics in Q4 2022 and held it in 1 quarter.
  • NinePointTwo Capital's SpringWorks Therapeutics position peaked at $281K in Q4 2022.
  • 148 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2023.

Based on NinePointTwo Capital's 13F filing for Q1 2023, filed 15 May 2023.